AFX-2421

AFX-2421 is a preclinical-stage small molecule therapeutic being developed by Afecta Pharmaceuticals for the treatment of interstitial cystitis (IC), also known as painful bladder syndrome. Interstitial cystitis is a chronic, debilitating condition characterized by bladder pressure, pelvic pain, and urinary urgency. While specific mechanistic details and the molecular target of AFX-2421 have not been publicly disclosed by the developer, the program is part of Afecta's pipeline focused on urological and inflammatory disorders. The drug is currently in the early stages of development, aiming to address the significant unmet medical need for effective pharmacological treatments for IC.